Moderna, Inc. (MRNA) PS Ratio: 8.25
Is Moderna, Inc.’s P/S ratio high or low?
Moderna, Inc.'s P/S ratio of 8.25 is 16% above its 5-year average of 7.12, near the low end of its 5-year range (2.22–71.00).
The P/S ratio for Moderna, Inc. (MRNA) is 8.25 as of Wednesday, June 10, 2026. It is above its 12-month average by 35.33% (6.10).
MRNA PS Ratio Chart
MRNA Average PS Ratio Chart
MRNA Current vs Average PS Ratio Chart
MRNA PS Ratio Metrics
PS RATIO
8.25
PS RATIO AVG TTM
6.10
PS RATIO AVG 3Y
5.20
PS RATIO AVG 5Y
7.12
PS RATIO AVG 10Y
52.48
PS RATIO AVG 15Y
52.48
PS RATIO AVG 20Y
52.48
CURRENT VS TTM AVG
+35.33%
CURRENT VS 3Y AVG
+58.67%
CURRENT VS 5Y AVG
+15.93%
CURRENT VS 10Y AVG
-84.28%
CURRENT VS 15Y AVG
-84.28%
CURRENT VS 20Y AVG
-84.28%
MRNA Competitors' PS Ratio
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Moderna, Inc. (MRNA) | — | 8.25 | 6.10 | 5.20 | 7.12 |
| Hologic, Inc. (HOLX) | $16.97B | 4.16 | 3.83 | 4.27 | 3.99 |
| BioNTech SE (BNTX) | $21.81B | 6.64 | 7.56 | 6.75 | 5.47 |
| Mettler-Toledo International Inc. (MTD) | $22.85B | 5.61 | 6.80 | 6.98 | 7.67 |
| Waters Corporation (WAT) | $23.83B | 7.97 | 6.60 | 6.58 | 6.83 |
| Align Technology, Inc. (ALGN) | $12.56B | 3.07 | 2.94 | 4.29 | 6.15 |
| Veeva Systems Inc. (VEEV) | $27.37B | 8.39 | 13.09 | 13.77 | 16.20 |
| Charles River Laboratories International, Inc. (CRL) | $9.06B | 2.29 | 2.13 | 2.36 | 3.08 |
| Bio-Rad Laboratories, Inc. (BIO) | $7.89B | 3.04 | 3.03 | 3.31 | 4.32 |
| Biogen Inc. (BIIB) | $29.00B | 2.96 | 2.43 | 2.85 | 3.13 |
P/S vs. its own history
At 8.25, P/S is in its normal range — richer than 51% of its 8-year range.
8-year low
2.22
median
7.19
8-year high
636.87
Sales Valuation
P/S Ratio
8.25
Market Cap / Annual Revenue
Moderna, Inc. PS Ratio Formula & Definition
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Moderna, Inc. PS Ratio FAQ
- What is the P/S ratio for Moderna, Inc. (MRNA)?
- The P/S ratio for MRNA stock is 8.25.
- Is Moderna, Inc.'s P/S ratio high or low?
- Moderna, Inc.'s P/S ratio of 8.25 is 16% above its 5-year average of 7.12, near the low end of its 5-year range (2.22–71.00).
- What is the TTM average P/S ratio for Moderna, Inc. (MRNA)?
- The TTM average P/S ratio for MRNA stock is 6.10.
- What is the 3Y average P/S ratio for Moderna, Inc. (MRNA)?
- The 3Y average P/S ratio for MRNA stock is 5.20.
- What is the 5Y average P/S ratio for Moderna, Inc. (MRNA)?
- The 5Y average P/S ratio for MRNA stock is 7.12.
- What is the 10Y average P/S ratio for Moderna, Inc. (MRNA)?
- The 10Y average P/S ratio for MRNA stock is 52.48.
- What is the 15Y average P/S ratio for Moderna, Inc. (MRNA)?
- The 15Y average P/S ratio for MRNA stock is 52.48.
- What is the 20Y average P/S ratio for Moderna, Inc. (MRNA)?
- The 20Y average P/S ratio for MRNA stock is 52.48.
Moderna, Inc. PS Ratio History
| DATE | PS RATIO |
|---|---|
| 2026-06-10 | 8.25 |
| 2026-06-09 | 8.47 |
| 2026-06-08 | 8.45 |
| 2026-06-05 | 8.42 |
| 2026-06-04 | 9.16 |
| 2026-06-03 | 8.71 |
| 2026-06-02 | 8.10 |
| 2026-06-01 | 8.18 |
| 2026-05-29 | 8.38 |
| 2026-05-28 | 8.45 |
| 2026-05-27 | 8.45 |
| 2026-05-26 | 8.35 |
| 2026-05-22 | 8.32 |
| 2026-05-21 | 8.39 |
| 2026-05-20 | 8.54 |
| 2026-05-19 | 8.12 |
| 2026-05-18 | 8.54 |
| 2026-05-15 | 8.71 |
| 2026-05-14 | 8.88 |
| 2026-05-13 | 8.95 |
| 2026-05-12 | 9.46 |
| 2026-05-11 | 9.39 |
| 2026-05-08 | 9.65 |
| 2026-05-07 | 8.62 |
| 2026-05-06 | 8.66 |
| 2026-05-05 | 8.29 |
| 2026-05-04 | 8.40 |
| 2026-05-01 | 8.05 |
| 2026-04-30 | 9.27 |
| 2026-04-29 | 9.22 |
| 2026-04-28 | 9.51 |
| 2026-04-27 | 9.83 |
| 2026-04-24 | 10.23 |
| 2026-04-23 | 10.66 |
| 2026-04-22 | 11.22 |
| 2026-04-21 | 10.94 |
| 2026-04-20 | 11.01 |
| 2026-04-17 | 10.84 |
| 2026-04-16 | 11.03 |
| 2026-04-15 | 10.95 |
| 2026-04-14 | 10.66 |
| 2026-04-13 | 10.22 |
| 2026-04-10 | 10.28 |
| 2026-04-09 | 10.35 |
| 2026-04-08 | 10.51 |
| 2026-04-07 | 10.11 |
| 2026-04-06 | 9.84 |
| 2026-04-02 | 9.93 |
| 2026-04-01 | 10.09 |
| 2026-03-31 | 10.25 |
| 2026-03-30 | 9.73 |
| 2026-03-27 | 10.00 |
| 2026-03-26 | 10.81 |
| 2026-03-25 | 10.80 |
| 2026-03-24 | 10.36 |
| 2026-03-23 | 10.35 |
| 2026-03-20 | 10.37 |
| 2026-03-19 | 10.57 |
| 2026-03-18 | 10.57 |
| 2026-03-17 | 10.88 |
| 2026-03-16 | 10.76 |
| 2026-03-13 | 10.60 |
| 2026-03-12 | 10.77 |
| 2026-03-11 | 11.29 |
| 2026-03-10 | 11.09 |
| 2026-03-09 | 11.25 |
| 2026-03-06 | 10.60 |
| 2026-03-05 | 10.86 |
| 2026-03-04 | 11.66 |
| 2026-03-03 | 10.05 |
| 2026-03-02 | 10.66 |
| 2026-02-27 | 10.81 |
| 2026-02-26 | 10.43 |
| 2026-02-25 | 10.36 |
| 2026-02-24 | 10.19 |
| 2026-02-23 | 10.15 |
| 2026-02-20 | 10.06 |
| 2026-02-19 | 8.73 |
| 2026-02-18 | 8.18 |
| 2026-02-17 | 7.71 |
| 2026-02-13 | 7.42 |
| 2026-02-12 | 7.04 |
| 2026-02-11 | 7.11 |
| 2026-02-10 | 7.38 |
| 2026-02-09 | 7.37 |
| 2026-02-06 | 7.20 |
| 2026-02-05 | 7.18 |
| 2026-02-04 | 7.51 |
| 2026-02-03 | 7.41 |
| 2026-02-02 | 7.47 |
| 2026-01-30 | 7.74 |
| 2026-01-29 | 8.23 |
| 2026-01-28 | 7.95 |
| 2026-01-27 | 7.98 |
| 2026-01-26 | 8.43 |
| 2026-01-23 | 8.55 |
| 2026-01-22 | 9.11 |
| 2026-01-21 | 8.75 |
| 2026-01-20 | 7.55 |
| 2026-01-16 | 7.35 |
| 2026-01-15 | 6.91 |
| 2026-01-14 | 7.13 |
| 2026-01-13 | 6.95 |
| 2026-01-12 | 5.94 |
| 2026-01-09 | 6.02 |
| 2026-01-08 | 5.95 |
| 2026-01-07 | 6.30 |
| 2026-01-06 | 6.26 |
| 2026-01-05 | 5.65 |
| 2026-01-02 | 5.42 |
| 2025-12-31 | 5.18 |
| 2025-12-30 | 5.34 |
| 2025-12-29 | 5.47 |
| 2025-12-26 | 5.48 |
| 2025-12-24 | 5.75 |
| 2025-12-23 | 5.67 |
| 2025-12-22 | 6.13 |
| 2025-12-19 | 5.94 |
| 2025-12-18 | 5.43 |
| 2025-12-17 | 5.36 |
| 2025-12-16 | 5.25 |
| 2025-12-15 | 5.25 |
| 2025-12-12 | 5.17 |
| 2025-12-11 | 5.20 |
| 2025-12-10 | 5.10 |
| 2025-12-09 | 4.96 |
| 2025-12-08 | 4.91 |
| 2025-12-05 | 4.86 |
| 2025-12-04 | 4.48 |
| 2025-12-03 | 4.42 |
| 2025-12-02 | 4.22 |
| 2025-12-01 | 4.24 |
| 2025-11-28 | 4.56 |
| 2025-11-26 | 4.39 |
| 2025-11-25 | 4.35 |
| 2025-11-24 | 4.24 |
| 2025-11-21 | 4.17 |
| 2025-11-20 | 3.93 |
| 2025-11-19 | 4.25 |
| 2025-11-18 | 4.38 |
| 2025-11-17 | 4.35 |
| 2025-11-14 | 4.35 |
| 2025-11-13 | 4.38 |
| 2025-11-12 | 4.69 |
| 2025-11-11 | 4.64 |
| 2025-11-10 | 4.35 |
| 2025-11-07 | 4.31 |
| 2025-11-06 | 4.27 |
| 2025-11-05 | 2.99 |
| 2025-11-04 | 3.01 |
| 2025-11-03 | 3.16 |
| 2025-10-31 | 3.44 |
| 2025-10-30 | 3.57 |
| 2025-10-29 | 3.13 |
| 2025-10-28 | 3.21 |
| 2025-10-27 | 3.38 |
| 2025-10-24 | 3.39 |
| 2025-10-23 | 3.33 |
| 2025-10-22 | 3.40 |
| 2025-10-21 | 3.49 |
| 2025-10-20 | 3.45 |
| 2025-10-17 | 3.30 |
| 2025-10-16 | 3.44 |
| 2025-10-15 | 3.51 |
| 2025-10-14 | 3.33 |
| 2025-10-13 | 3.39 |
| 2025-10-10 | 3.40 |
| 2025-10-09 | 3.49 |
| 2025-10-08 | 3.54 |
| 2025-10-07 | 3.47 |
| 2025-10-06 | 3.49 |
| 2025-10-03 | 3.61 |
| 2025-10-02 | 3.60 |
| 2025-10-01 | 3.50 |
| 2025-09-30 | 3.28 |
| 2025-09-29 | 3.21 |
| 2025-09-26 | 3.11 |
| 2025-09-25 | 3.12 |
| 2025-09-24 | 3.28 |
| 2025-09-23 | 3.27 |
| 2025-09-22 | 3.37 |
| 2025-09-19 | 3.20 |
| 2025-09-18 | 3.23 |
| 2025-09-17 | 3.17 |
| 2025-09-16 | 3.15 |
| 2025-09-15 | 3.03 |
| 2025-09-12 | 2.98 |
| 2025-09-11 | 3.22 |
| 2025-09-10 | 3.08 |
| 2025-09-09 | 3.10 |
| 2025-09-08 | 3.15 |
| 2025-09-05 | 3.19 |
| 2025-09-04 | 3.08 |
| 2025-09-03 | 3.05 |
| 2025-09-02 | 3.07 |
| 2025-08-29 | 3.05 |
| 2025-08-28 | 3.10 |
| 2025-08-27 | 3.18 |
| 2025-08-26 | 3.14 |
| 2025-08-25 | 3.21 |
| 2025-08-22 | 3.44 |
| 2025-08-21 | 3.32 |
| 2025-08-20 | 3.41 |
| 2025-08-19 | 3.54 |
| 2025-08-18 | 3.56 |
| 2025-08-15 | 3.55 |
| 2025-08-14 | 3.38 |
| 2025-08-13 | 3.41 |
| 2025-08-12 | 3.25 |
| 2025-08-11 | 3.23 |
| 2025-08-08 | 3.31 |
| 2025-08-07 | 3.37 |
| 2025-08-06 | 3.39 |
| 2025-08-05 | 3.48 |
| 2025-08-04 | 3.50 |
| 2025-08-01 | 3.50 |
| 2025-07-31 | 3.63 |
| 2025-07-30 | 3.95 |
| 2025-07-29 | 4.02 |
| 2025-07-28 | 4.17 |
| 2025-07-25 | 4.20 |
| 2025-07-24 | 4.18 |
| 2025-07-23 | 4.26 |
| 2025-07-22 | 4.02 |
| 2025-07-21 | 3.81 |
| 2025-07-18 | 3.84 |
| 2025-07-17 | 3.96 |
| 2025-07-16 | 3.94 |
| 2025-07-15 | 3.88 |
| 2025-07-14 | 4.04 |
| 2025-07-11 | 4.14 |
| 2025-07-10 | 4.22 |
| 2025-07-09 | 4.03 |
| 2025-07-08 | 4.00 |
| 2025-07-07 | 3.68 |
| 2025-07-03 | 3.75 |
| 2025-07-02 | 3.72 |
| 2025-07-01 | 3.53 |
| 2025-06-30 | 3.39 |
| 2025-06-27 | 3.34 |
| 2025-06-26 | 3.39 |
| 2025-06-25 | 3.30 |
| 2025-06-24 | 3.30 |
| 2025-06-23 | 3.16 |
| 2025-06-20 | 3.18 |
| 2025-06-18 | 3.12 |
| 2025-06-17 | 3.14 |
| 2025-06-16 | 3.20 |
| 2025-06-13 | 3.28 |
| 2025-06-12 | 3.36 |
| 2025-06-11 | 3.41 |
| 2025-06-10 | 3.40 |
| 2025-06-09 | 3.46 |
| 2025-06-06 | 3.38 |
| 2025-06-05 | 3.21 |
| 2025-06-04 | 3.35 |
| 2025-06-03 | 3.42 |
| 2025-06-02 | 3.33 |
| 2025-05-30 | 3.27 |
| 2025-05-29 | 3.31 |
Showing the most recent 260 of 1,886 data points. The chart above shows the full history.
Related Metrics
About Moderna, Inc.
Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stéphane Bancel